{Reference Type}: Journal Article
{Title}: Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
{Author}: Bataller A;Gener-Ricos G;Almanza-Huante E;Chien KS;Urrutia S;Bazinet A;Rodriguez-Sevilla JJ;Hammond D;Sasaki K;Takahashi K;DiNardo CD;Ravandi F;Borthakur G;Kadia TM;Kanagal-Shamanna R;Kantarjian HM;Garcia-Manero G;Montalban-Bravo G;
{Journal}: Blood Adv
{Volume}: 8
{Issue}: 11
{Year}: 2024 Jun 11
{Factor}: 7.637
{DOI}: 10.1182/bloodadvances.2024012565
{Abstract}: <B>UNASSIGNED: </B>Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic leukemia (tCMML; n = 71) and compared its features to that of de novo CMML (dnCMML; n = 461). Median time from cytotoxic therapy to tCMML diagnosis was 6.5 years. Compared with dnCMML, chromosome-7 abnormalities (4% vs 13%; P = .005) but not complex karyotype (3% vs 7%; P = .15), were more frequent in tCMML. tCMML was characterized by higher TP53 mutation frequency (4% vs 12%; P = .04) and lower NRAS (6% vs 22%, P = .007) and CBL (4% vs 12%, P = .04) mutation frequency. Prior therapy with antimetabolites (odd ratio [OR], 1.22; 95% confidence interval [CI], 1.05-1.42; P = .01) and mitotic inhibitors (OR, 1.24; 95% CI, 1.06-1.44; P = .009) was associated with NF1 and SETBP1 mutations whereas prior mitotic inhibitor therapy was associated with lower TET2 mutation frequency (OR, 0.71; 95% CI, 0.55-0.92; P = .01). Although no differences in median overall survival (OS) were observed among tCMML and dnCMML (34.7 months vs 35.9 months, P = .26), multivariate analysis for OS revealed that prior chemotherapy was associated with increased risk of death (hazard ratio, 1.76; 95% CI, 1.07-2.89; P = .026). Compared with a cohort of therapy-related myelodysplastic syndrome, tCMML had lower TP53 mutation frequency (12% vs 44.4%, P < .001) and less unfavorable outcomes. In summary, tCMML does not exhibit the high-risk features and poor outcomes of t-MNs.